Boule Diagnostics AB (publ) BOUL.ST
Nasdaq Stockholm · Healthcare · Medical Devices
1.22 SEK
−4.3%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Boule Diagnostics
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 548 | 571 | 558 | 490 |
| EBITDA | 58 | 66 | −325 | 40 |
| Net income | 13 | 25 | −297 | −4 |
| Balance sheet | ||||
| Equity | 463 | 475 | 196 | 168 |
| Total debt | 190 | 166 | 195 | 224 |
| Cash | 97 | 37 | 23 | 20 |
| Net debt | 93 | 129 | 172 | 204 |
| Ratios and per share | ||||
| EBITDA margin | 10.6% | 11.5% | −58.3% | 8.2% |
| Profit margin | 2.3% | 4.4% | −53.1% | −0.8% |
| Return on equity | 2.8% | 5.3% | −151.0% | −2.2% |
| Earnings/share (SEK) | 0.33 | 0.64 | −7.64 | −0.10 |
| Book value/share (SEK) | 11.91 | 12.23 | 5.06 | 4.32 |
| Shares outstanding (M) | 39 | 39 | 39 | 39 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | 0.3 |
| EV / EBITDA | 6.2 |
| Net debt / EBITDA | 5.1 |
| Return on equity | −2.2% |
| Profit margin | −0.8% |
| Beta 1Y | 0.47 |
| Revenue growth 1Y | −12.3% |
| Revenue CAGR 3Y | −3.7% |
| ROE avg. 3Y | −49.3% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2022 | 0.39 |
Not investment advice. Figures may contain errors from the data source.